Caribou Biosciences, Inc. (CRBU) Reports Q3 Loss, Lags Revenue Estimates
Portfolio Pulse from
Caribou Biosciences, Inc. (CRBU) reported a Q3 loss of $0.38 per share, which was better than the Zacks Consensus Estimate of a $0.44 loss. However, this is a larger loss compared to the $0.12 per share loss from the previous year.
November 07, 2024 | 12:30 am
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Caribou Biosciences reported a Q3 loss of $0.38 per share, better than the expected $0.44 loss but worse than last year's $0.12 loss.
The reported loss per share was better than expected, which is a positive sign, but the increase in loss compared to last year may concern investors. This mixed result is likely to have a neutral short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100